Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Okyo Pharma Limited ADR (OKYO)

Okyo Pharma Limited ADR (OKYO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,829
  • Shares Outstanding, K 33,836
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,830 K
  • EBIT $ 0 M
  • EBITDA $ -16 M
  • 60-Month Beta -0.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3101 +29.72%
on 05/02/25
1.9800 -14.17%
on 05/21/25
+0.3595 (+26.83%)
since 04/22/25
3-Month
1.0300 +65.00%
on 04/08/25
1.9800 -14.17%
on 05/21/25
+0.5845 (+52.42%)
since 02/21/25
52-Week
0.8075 +110.46%
on 08/05/24
1.9800 -14.17%
on 05/21/25
+0.2064 (+13.82%)
since 05/22/24

Most Recent Stories

More News
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

BALTIMORE, MD / ACCESS Newswire / January 30, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a...

OKYO : 1.7300 (+4.85%)
S&P Futures Climb Ahead of Key U.S. PPI Data, ECB Decision in Focus

September S&P 500 futures (ESU23) are trending up +0.29% this morning after three major U.S. benchmark indices ended the regular session mixed as investors digested the latest U.S. inflation report while...

PCT : 8.29 (+1.84%)
JBHT : 138.14 (-0.88%)
F : 10.37 (-1.05%)
AAL : 11.42 (+1.60%)
CCL : 22.31 (+1.23%)
SMTC : 38.44 (-0.18%)
CPRT : 60.75 (-0.56%)
FSLR : 156.73 (-4.06%)
LEN : 104.79 (-0.80%)
OKYO : 1.7300 (+4.85%)
ADBE : 415.31 (+0.31%)
ESU23 : 4,491.72s (-0.32%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

OKYO : 1.7300 (+4.85%)
JNJ : 152.49 (-0.45%)
ALC : 86.78 (-0.87%)
BLCO : 11.28 (+0.80%)
RHHBY : 38.9040 (-1.23%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...

OKYO : 1.7300 (+4.85%)
JNJ : 152.49 (-0.45%)
ALC : 86.78 (-0.87%)
BLCO : 11.28 (+0.80%)
RHHBY : 38.9040 (-1.23%)
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

ALDX : 2.31 (+2.67%)
OKYO : 1.7300 (+4.85%)
EYPT : 5.84 (-0.51%)
NVS : 111.70 (-0.96%)
OKYO.LN : 1.400 (-24.32%)
OCUL : 7.29 (-0.14%)
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

/PRNewswire/ -- The Global Dry Eye Syndrome market is witnessing continued growth due to the factors such as the growing demand for effective treatments, the...

ALDX : 2.31 (+2.67%)
OKYO : 1.7300 (+4.85%)
EYPT : 5.84 (-0.51%)
NVS : 111.70 (-0.96%)
OCUL : 7.29 (-0.14%)
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans a Q4 2022...

OKYO : 1.7300 (+4.85%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing

LONDON and NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing...

OKYO : 1.7300 (+4.85%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing

LONDON and BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and...

OKYO : 1.7300 (+4.85%)
OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused...

OKYO : 1.7300 (+4.85%)
OKYO.LN : 1.400 (-24.32%)
EMMLF : 0.0137 (-32.51%)

Business Summary

OKYO Pharma Limited is a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain. OKYO Pharma Limited is based in LONDON.

See More

Key Turning Points

3rd Resistance Point 2.2400
2nd Resistance Point 2.1100
1st Resistance Point 1.8800
Last Price 1.7300
1st Support Level 1.5200
2nd Support Level 1.3900
3rd Support Level 1.1600

See More

52-Week High 1.9800
Last Price 1.7300
Fibonacci 61.8% 1.5321
Fibonacci 50% 1.3937
Fibonacci 38.2% 1.2554
52-Week Low 0.8075

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar